Simulated pipeline for caloric-restriction-mimicking drug candidates
Caloric restriction extends lifespan in many species; mimetics aim to copy that effect pharmacologically.
CR mimetics target the same nutrient-sensing pathways activated by restriction.
Sustained restriction is impractical for most people, motivating a drug alternative.
Placeholder: mimetics could deliver benefits without dietary restriction.
Large compound libraries are screened against CR-pathway biomarkers to find candidate hits.
Placeholder: reporter assays flag compounds that activate CR-linked pathways.
Placeholder: counter-screens remove non-specific and toxic hits.
Placeholder: most hits fail confirmatory screening.
Surviving hits are tested in yeast, worms, and mice to confirm lifespan and healthspan effects.
Placeholder: effects must replicate across multiple model organisms.
Placeholder: toxicity and dose-response are characterized early.
Placeholder: cross-species consistency raises translational confidence.
Medicinal chemistry improves potency, selectivity, and pharmacokinetics of surviving leads.
Placeholder: iterative chemistry improves target engagement.
Placeholder: absorption and stability are optimized for dosing.
Placeholder: optimization narrows the field to few final leads.
The optimized lead advances through regulatory and clinical trial phases toward approval.
Placeholder: preclinical data package supports an IND-style filing.
Placeholder: safety, efficacy, and scale are tested in sequence.
Placeholder: most candidates do not reach approval.